➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Medtronic
Colorcon
Baxter
Johnson and Johnson
Mallinckrodt

Last Updated: September 20, 2021

DrugPatentWatch Database Preview

Claims for Patent: 10,052,381

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 10,052,381
Title:Classifiers of NF-.kappa.B pathway activation, devices, and methods of use thereof
Abstract: This disclosure relates to classifiers of NF-.kappa.B pathway activation, devices, and methods of use thereof. In certain embodiments, the disclosure relates to methods comprising measuring changes in expression of genes controlled by p105 in a sample providing a detected p105 controlled gene expression pattern. In certain embodiments, the methods further comprise measuring changes in expression of genes controlled by p100 in a sample providing a detected p100 controlled gene expression pattern. In certain embodiments, the methods further comprise the step of comparing the detected p105 controlled gene expression patterns to a predetermined gene pattern and/or the detected p100 controlled gene expression patterns to a predetermined pattern.
Inventor(s): Bernal-Mizrachi; Leon (Atlanta, GA)
Assignee: Emory University (Atlanta, GA)
Application Number:15/482,353
Patent Claims:1. A method of diagnosing and treating lymphoma comprising: measuring in a lymphoma cell of a subject an increased RNA expression of HLA-F, HLA-E, ICAM-1, ZFAND3, LMNA, FAM65A, BIRC7, EXD3, SYNPO, TNS4 and a decreased RNA expression of NFE2L, NCOA1, JUNB, RASSF4, C2, PLXND1, DENND3, and PPARD compared to a non-tumor cell; diagnosing the subject with a canonical NF-.kappa.B activation pattern; and administering an effective amount of rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone to the subject in need thereof.

2. A method of diagnosing and treating lymphoma comprising: measuring in a lymphoma cell of a subject an increased RNA expression of EIP4E, HSPD1, SFRS3, COX11, SEH1L, SETMAR, NIP7 and a decreased RNA expression of USP1, DNAJC9, CCDC99, FAM29A, MCM10, C 12orf48, PBK, MSH2, DHFR, CCNA2, MAD2L1, KIF11, and ECT2 compared to a non-tumor cell; diagnosing the subject with a non-canonical NF-.kappa.B activation pattern; and administering an effective amount of rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine, prednisone, and another anticancer agent to the subject in need thereof.

Details for Patent 10,052,381

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26 ⤷  Free Forever Trial Emory University (Atlanta, GA) 2032-09-20 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26 ⤷  Free Forever Trial Emory University (Atlanta, GA) 2032-09-20 RX search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22 ⤷  Free Forever Trial Emory University (Atlanta, GA) 2032-09-20 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22 ⤷  Free Forever Trial Emory University (Atlanta, GA) 2032-09-20 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Baxter
McKinsey
Boehringer Ingelheim
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.